Navigation Links
S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders

SINGAPORE, May 13 /PRNewswire/ -- S*BIO Pte Ltd today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB1518, its potent and orally-active JAK2 inhibitor for the treatment of myeloproliferative disorders (MPD). The FDA accepted S*BIO's application upon review of preclinical data which demonstrated excellent anti-proliferative and anti-tumor activity, combined with very good tolerability of the JAK2 inhibitor.

"We are pleased to receive orphan drug designation for SB1518," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "There is a great need for effective treatment of MPD caused by aberrant JAK2 signaling and SB1518 could potentially address this unmet medical need. The designation will allow us to optimize our development and regulatory strategy for SB1518."

MPD is a closely related group of hematological malignancies in which the bone marrow develops and functions abnormally. MPD is characterised by an excess of blood cells and the three main disorders include polycythemia vera (excess red blood cell mass), essential thrombocythemia (excess blood platelets) and myelofibrosis.

Orphan Drug Designation in the United States

Orphan drug is a designation by the FDA indicating a therapy developed to treat diseases that affect fewer than 200,000 persons in the United States. Orphan drug designation for SB1518 will entitle S*BIO to tax credits on clinical research after designation and seven years of marketing exclusivity. Other potential benefits include regulatory fee waivers, grants for clinical research and protocol assistance.

About SB1518

SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in certain types of hematological disorders. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of a variety of cancers and other hematological disorders.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, has entered the clinic in 2007. It recently announced that SB1518, has been selected as a clinical candidate and that a third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by an experienced clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at

S*BIO Pte Ltd: Russo Partners:

Stephen Keith Rhind, Ph.D. Tony Russo +1 212-845-4251

Senior Vice President, Corporate

Development Andreas Marathovouniotis

Tel: +65 6827 5000 (Singapore) +1 212-845-4235

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
(Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced that ... closed system for isolating adipose-derived stem cells. The announcement starts a new phase toward ... SVF is a component of the lipoaspirate obtained from liposuction of excess adipose tissue. ...
(Date:11/30/2015)... ... ... Cells Group announced the opening of a new core patient care hub with the ... The facilities are part of GSCG’s expansion efforts in Latin America. , Both the ... to patients from around the world. , The clinics will be headed by Victor Perez, ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
Breaking Biology Technology:
(Date:11/30/2015)... DEERFIELD BEACH, Fla. , Nov. 30, 2015 ... selected as a finalist in this year,s Fierce Innovation ... publisher of FierceHealthIT , ... BIOCLAIM was recognized as a finalist in the ... --> ...
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):